Prostate cancer is the second most common cancer in American men.  While the disease is prevalent across the country, the screening guidelines are not.  Prostate cancer screenings have always been somewhat controversial because the tests often alert physicians to the presence of cancer, but there is no precise way to determine, definitively, whether the cancer […]

Learn More

As the COVID-19 pandemic continues, many cancer patients are having to make the difficult decision to continue with their current cancer regimen or delay treatments.  Cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the risk of COVID-19. To help ease these decisions, several peer-reviewed, non-profit cancer care organizations […]

Learn More

When deciding which treatment option is best for their prostate cancer, men take numerous factors into consideration.  While their physician’s recommendation does play an important role in the treatment decision, in the end, most men make the choice that is best for them.  That choice is often based on treatment outcomes and side effects, and […]

Learn More

Accuray Incorporated, developer and manufacturer of the CyberKnife® System, announced that published data from two multicenter studies using differing protocols provide consistent results and reinforce the use of the CyberKnife system for the effective management of low-and intermediate-risk prostate cancer.  The studies are the largest conducted to date evaluating stereotactic body radiation therapy (SBRT) in […]

Learn More

Learn More

Last week, the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) released collaborative clinical guidelines for managing localized prostate cancer which offers a framework for shared decision-making between physicians and patients.  Through this collaboration, the committee provided guidance on active surveillance and on which treatments […]

Learn More

The U.S. Preventive Services Task Force (USPSTF) recently updated their prostate screening recommendations. On April 11, 2017, the USPSTF issued an updated draft recommendation on screening for prostate cancer.  The updated recommendation changes the grade for PSA-based screening from “D” to “C” for men 55 – 69 years of age.  As a result, the USPSTF […]

Learn More

Watch general surgeon, Dr. Louis Heuser, talk about why he chose CyberKnife for the treatment of his prostate cancer. Dr. Heuser was very happy with the quick treatments and the fact that he was able to stay close to home and continue to work and see his patients. It’s Your Prostate, Your Cancer, Your Choice.

Learn More

Accuray Incorporated, the manufacturer of the CyberKnife® Robotic Radiosurgery System, recently announced data from a study which showed that treatment with the CyberKnife System for low and intermediate risk prostate cancer provides excellent long-term results. The seventeen center study, which was presented last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO […]

Learn More

One of the ways you can reduce your risk for cancer is by getting screening tests that can help find cancer at an early stage, before symptoms appear. When abnormal tissue or cancer is found early, it may be easier to treat or cure.  By the time symptoms appear, the cancer may have grown and […]

Learn More